Nasdaq · Healthcare

Relay Therapeutics, Inc. (RLAY)

As-reported financials and recent SEC filings for Relay Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$15.4M

Net income

$-276.5M

Net margin

—

Diluted EPS

$-1.61

ROE

-48.8%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$15.4M	$10.0M	$25.5M	$1.4M	$3.0M
Gross profit	—	—	—	—	—
Operating income	$-302.7M	$-372.5M	$-373.0M	$-299.3M	$-364.7M
Net income	$-276.5M	$-337.7M	$-342.0M	$-290.5M	$-363.9M
Diluted EPS	$-1.61	$-2.36	$-2.79	$-2.59	$-3.82

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-07-02

1442026-06-30

42026-06-24

42026-06-24

1442026-06-22

1442026-06-22

42026-06-10

42026-06-10

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on RLAY

Search Relay Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.